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In the last year there have been two great leaps in 
the development of therapies against metastatic 
melanoma. A phase III trial of a new antibody treat-
ment showed an overall survival improvement, 
and a separate phase I trial of a kinase inhibitor 
yielded significant tumour load reductions. In June, 
the New England Journal of Medicine released the 
results of a 676 patient phase III trial in melanoma 
showing, for the first time, improvement in the 
overall survival of metastatic patients upon treat-
ment with a CTLA-4 blocking antibody (Ipilimum-
ab). CTLA-4 down-regulates T-cell activation and is 
important for effecting cancer cell immune escape. 
By blocking CTLA-4 with the Ipilimumab antibody, 
T-cell activation is allowed to progress unhindered. 
The authors reported that under antibody treat-
ment patient survival was increased by a median 
of four months [1]. A few months later, the same 
journal published a phase I trial which had used 
a carefully designed small-molecule (PLX4032) to 
treat 32 specifically selected metastatic melanoma 
patients. PLX4032 acts by selectively inhibiting the 
mutated form of a kinase (BRAF) involved in driv-
ing melanoma cell proliferation. The mutation, 
which constitutively activates BRAF, is present in 
more than half of all melanomas. The trial authors 
found that PLX4032 treatment resulted in signifi-
cant (sometimes spectacular) reductions in the tu-
mour load of 25 patients [2]. These two trials show-
case long-sought breakthroughs in the treatment 
of metastatic melanoma and end decades of what 
has been unremitting failure. 
Behind these scenes of clinical success a quieter 
revolution has been brewing. In the last few years, 
critical developments in our understanding of 
metastatic melanoma have prompted the rise of 
two new schools of thought concerning how mela-
noma may progress from a small primary lesion to 
a widely dispersed (and lethal) metastatic disease. 
While the hypotheses these schools champion ap-
pear at first glance to be diametrically opposed, 
there are signs of reconciliation which promise to 
yield a unified and comprehensive "theory of pro-
gression".
Until recently, clinicians and researchers had as-
sumed that after the initial transformation event, 
in which a normal cell is committed to a malignant 
fate, the disease progresses by evolving from be-
ing weakly metastatic to a dangerously aggres-
sive state. It was thought that during disease pro-
gression cancer cells continue to acquire genetic 
changes which increase their capacity to prolifer-
ate, avoid cell death and invade tissues, and thus 
follow a linear progression of increasing metastatic 
potential. It was hoped that markers of this pro-
gression might also be useful as prognostic tools 
or even targets for immunotherapy and drug inter-
vention. Unfortunately, genetic changes which re-
liably correlate with melanoma stage progression 
have not yet been positively identified.
Not long ago it was recognized by some research-
ers that the evolutionary model of cancer progres-
sion was not sufficient to explain the data coming 
out of scientific and clinical laboratories. For exam-
ple, whenever a new marker was associated with 
disease progression closer examination would re-
veal that its expression in melanoma tissue is quite 
heterogeneous. A protein reported to be only ex-
pressed in the primary lesion, would haphazardly 
reappear in metastatic tissues. Findings such as 
these suggested that cancers were considerably 
more plastic entities than evolutionary models al-
low. Indeed, melanoma lesions are particularly het-
erogeneous in their cellular make-up. While it has 
long been known that lesions include, in addition 
to melanoma cells, a variety of other cell types, it is 
only recently that we have come to appreciate the 
considerable intra-lesional variation which exists 
between melanoma cells. Cancer stem cell theory, 
originating from studies performed on acute my-
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Figure 1 – The phenotype switching model of melanoma progression. The lesion grows via proliferation of proli-
ferative phenotype melanoma cells. Increasing levels of hypoxia inflammation likely contribute to the switching 
of many cells to an invasive phenotype which then escape the lesion and penetrate distal regions of the body. A 
small number of invasive phenotype cells are able to switch back to the proliferative phenotype and renew the 
cycle.
eloid leukemia, proposes that within every lesion 
there is a tiny population of cells that resemble the 
stem cells of normal tissues [3]. Cancer stem cells 
replicate slower than other cancer cells, but can 
do so indefinitely, and they can give rise to faster 
replicating daughter cells with different (differenti-
ated) characteristics that make up the bulk of the 
tumour. These daughter cells are presumed to en-
counter replicative exhaustion and thus could not 
provide the seed for other metastases. Therefore it 
is proposed that a small population of cancer stem 
cells is wholly responsible for continuous disease 
progression. This model explains cellular heteroge-
neity very well, as normal stem cells are known to 
give rise to differently committed daughter cells. 
It may well also explain melanoma’s persistent 
resistance to therapy, as cells being targeted may 
be the bulk-population of fast-cycling daughters, 
leaving slow-cycling cancer stem cells untouched. 
To support the notion of a melanoma stem cell, 
some melanoma researchers have reported the 
isolation of small, specific populations of cells di-
rectly from melanoma tissues which alone retain 
the tumorigenic activity necessary for driving met-
astatic progression [4]. But findings such as these 
have been challenged and the tools used to derive 
them brought into question. For example, a group 
injecting randomly selected single melanoma cells 
into an animal model reported that as much as a 
quarter of any given lesion’s melanoma cell popu-
lation is tumorigenic [5]. This and other findings 
have convinced a significant proportion of mela-
noma researchers that the cancer stem cell model 
may not be sufficient to explain melanoma biology 
[6,7].
Other studies of melanoma cell heterogeneity 
have led to the development of a significantly dif-
ferent model for disease progression. These inves-
tigations have mostly been based on studies of 
melanoma cell cultures. Melanoma cell culturing 
is, for some clinics, a routine procedure designed 
to ensure that patient materials may be stored for 
an indefinite period in a form which is easily ana-
lyzable. If, for example, you wish to check for a par-
ticular mutation, one need only thaw out and grow 
sufficient cells in the lab, extract DNA and perform 
the necessary (and now-a-days trivial) experiments 
to get the required data. So there are a significant 
number of sites around the world which maintain 
stocks of patient-derived melanoma cell cultures. 
In many of these sites it has been noticed that the 
expression of a specific collection of several hun-
dred genes can be used to collect culture samples 
into recognizably distinct groups. Unfortunately, 
this grouping shows no relationship with patient 
metrics [8]. These gene expression signatures aren’t 
even patient-specific, as a single patient with multi-
ple lesions can yield melanoma cultures belonging 
to either group. While this taxonomy of two mela-
noma cell gene expression signatures was initially 
mysterious, it was soon discovered that there are 
important differences in the in vitro behaviours of 
cell cultures from different groups. The samples of 
one group express melanocytic markers and prolif-
erate well, but (relative to the other group) are less 
invasive. The more invasive samples of the other 
group, however, express few melanocytic mark-
ers and often do not proliferate as well as the first 
group. This and similar data was pointing to the 
fact that any given melanoma cell culture tended 
towards having either a proliferative or an invasive 
phenotype. This raised difficult questions. For ex-
ample, metastatic potential invokes the capacity 
for both proliferation and invasion. Why were the 
cell cultures expressing one or the other of these 
characteristics? How could proliferative cultures 
with weakly invasive characteristics nevertheless 
derive from aggressive and distal metastases?  A 
possible answer emerged when these cells were 
injected subcutaneously into nude mice (a labora-
tory animal model without a functioning thymus 
and thus very few T cells, useful for growing dif-
ferent tissues and cells without fear of rejection). 
It was found that while there was a significant dif-
ference in growth kinetics (proliferative cultures 
initiated tumourigenesis weeks sooner than inva-
sive cultures) nearly all injected cultures resulted 
in tumours regardless of phenotype. Critically, im-
munohistochemical analysis of these xenografts 
showed the presence of both phenotypes in each. 
This indicated that either phenotype was capable 
of being derived from the other, that a form of 
switching had taken place in some of the cells dur-
ing tumourigenesis [9]. Phenotype, while a fixed 
characteristic in vitro, is not fixed in vivo.
These findings have led to the derivation of a strik-
ingly novel hypothesis, termed the phenotype 
switching model for melanoma progression. The 
concept is one in which melanoma cells shuttle 
back-and-forth between states of invasiveness and 
proliferation in response to changing microenvi-
ronmental cues. This model explains why cultures 
of either phenotype may be obtained at any stage, 
with each lesion growing to become a patchwork 
of both. It offers a reason for why the disease is so 
resistant to standard chemotherapies, which at-
tack rapidly proliferating cells but would have little 
effect on slowly proliferating invasive phenotypes, 
cells which can later provide the source for prolif-
erative phenotypes after treatment is halted. Im-
munotherapies which target melanocytic markers 
are also compromised by an invasive population 
which simply does not express them.
There are conspicuous correlations between the 
phenotype switching model and the idea that 
melanoma is propagated by stem cells. Cancer 
stem cells are thought to proliferate slowly, self-
renew, provide a reservoir of therapy-resistant cells 
as well as seed and maintain tumours. All of these 
are mirrored by the invasive population described 
by the phenotype switching model. Furthermore, 
cancer stem cells studies are emerging from mela-
noma labs which reveal them as being plastic in 
their expression of defining markers. For example, 
Meenhard Herlyn’s group published a study in 
which they identify JARID1B as a melanoma stem 
cell marker, but show that its expression is dynam-
ic and not actually necessary for seeding tumours 
[10]. One has to wonder, as researchers continue 
to redefine what passes for a cancer stem cell to 
the point that even marker expression is not a 
fixed characteristic, whether or not the differences 
between invasive phenotype melanoma cells and 
what are thought to be melanoma stem cells are 
simply those of semantics?  The immediate future 
holds that the perceived cellular landscape for 
melanoma is about to undergo a sharp paradigm, 
as more and more researchers come to accept the 
shape-shifting nature of these cells, and that the 
standard cancer stem cell model simply does not R
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apply to melanoma [7]. 
Enthusiasm over the recent successes with Ipili-
mumab and PLX4032 should be tempered by an 
appreciation of their limits. Ipilimumab grants an 
average life extension which is shorter than half 
a year. PLX4032 can effect startling reductions 
in tumor mass, but there is no evidence that this 
translates to extended survival. Melanoma is still 
killing the patients for whom these therapies have 
a significant effect. Examining therapy response in 
the context of new cellular hypotheses such as the 
phenotype switching model of melanoma progres-
sion has the potential to extend these gains.
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